 PITTSBURGH, April 26, 2021 GLOBE NEWSWIRE -- Krystal Biotech Inc., Krystal NASDAQ: KRYS, the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistical Analysis Plan SAP in the ongoing Phase 3 study of B-VEC for the treatment of dystrophic epidermolysis bullosa DEB based on feedback from the U.S. Food and Drug Administration FDA. 